We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Your Password has changed! Please login again
Cart
Outdated Browser Detected
Our website has detected that you are using an outdated browser that will prevent you from accessing certain features.
Please use one of the below recommended browsers to improve your browsing experience
West Celebrates the One-Year Anniversary of Integrated Solutions
West is now celebrating the one-year anniversary of its Integrated Solutions initiative, known as Simplify the Journey™. Throughout 2019, we socialized the program through marketing materials and face-to-face conversations with customers. Now it’s time to reflect on the lessons we’ve learned — and to look forward to the opportunities on the horizon.
As injectable medicines have evolved, customers have expressed a need for partners that can offer a more holistic approach encompassing the entire lifecycle of an injectable medicine, from early clinical development to commercialization. The Integrated Solutions initiative from West, now celebrating its one-year anniversary, does exactly that, bringing together West’s primary packaging, device, analytical, regulatory and contract manufacturing expertise in a single-source solution.
A New Approach for All Customers
The Integrated Solutions initiative elevates West’s role as a partner and collaborator. Our goal is to complement, not duplicate, the functional capabilities of our customers. This enables them to focus on their core competencies while relying on West for services they may not have or plan to have inhouse. As such, with Integrated Solutions in place, we can offer something to every customer, regardless of their size or where their products sit in the development lifecycle.
According to Jennifer Riter, Senior Director, Analytical Services, “We always knew smaller pharma companies could benefit from this type of bundled solution because they simply don’t have the internal resources to accommodate the full range of services West offers. But we were excited to learn how many larger companies were willing, even eager, to engage us in conversations about how we could help.”
The willingness of customers to engage about an Integrated Solutions approach is directly related to the changes and challenges taking place across the industry. “There are a number of trends driving drug and device manufacturing,” Riter points out. “The continued focus on combination products, as well as many pipelines containing complex molecules, are just a few examples.” As companies struggle to respond to these drivers, they face gaps in experience and knowledge. “Integrated Solutions affords West the opportunity to fill these gaps, to leverage the expertise we’ve acquired over nearly 100 years of manufacturing containers, closures and delivery devices for injectable medicines.”
The Journey Continues
Integrated Solutions is a year old, but in reality, West has been offering many of these services independently to customers for over 20 years. Formalizing the name and providing more structure to the program allows us to truly share with our customers what we have learned and how this knowledge can help address our customer’s needs and challenges.
Looking forward, Integrated Solutions will continue to evolve based on industry needs and challenges. As it does, one thing is certain: West is committed to the program because an integrated, comprehensive approach is required for the rapidly changing pharmaceutical landscape.
As Riter points out, “Ultimately, Integrated Solutions is about bringing together the right drugs, devices, and services needed to ensure the best overall patient experience. But the complexities involved to deliver that ultimate experience are significant. It takes collaboration — between manufacturers and external providers like West — and an interconnected suite of services to ensure a product makes it to the market and is used by the people who need it.”
Simplify the Journey™ is a trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
The traditional way to package injectable drugs is to place them in a stoppered vial. The stopper is typically held in place with an aluminum ferrule that is called a seal. The vial seal is crimped onto the vial and not only serves to keep the stopper secured to the vial and the <a href="/zh-cn/blog/2018/february/minimize-microbial-contamination-with-flip-off-seals">vial contents sterile<sup>i</sup></a> but also protects the injection site on the stopper and provides a means of demonstrating lack of tampering.
West turns 100 this year! A milestone we are very proud of, and something few companies have the opportunity to celebrate. Today, we are a global market leader who is defining the evolution of our industry. AND that’s the way West has operated since the beginning.
The revision to the United States Pharmacopeia (USP) General Chapter <1> Injections, Labeling on Ferrules and Cap Overseals standard becomes official on December 1, 2013. The revision will limit printing to <span style="text-decoration: underline;">only</span> cautionary statements on the top surface of the ferrule or cap overseal of a vial containing an injectable drug product sold within the United States. Seals with the embossed “Flip-Off” or printed with other non-cautionary labeling will not be compliant with this new standard.
West Pharmaceuticals will participate in two poster presentation sessions at the <a href="https://www.pda.org/"><span style="text-decoration: underline;">Parenteral Drug Association (PDA) Annual Meeting</span></a>, taking place March 16-18, 2015 in Las Vegas. During the meeting, West will also showcase innovations in integrated drug packaging and delivery systems that help ensure the quality, safety and efficacy of injectable drug products for pharmaceutical and biotechnology manufacturers worldwide at booth #405.
<span style="color: #000000;">In a recent Flash Report, Rx-360.org offered a summary of the proposed USP Chapter 1083 – Good Distribution Practices – Supply Chain Integrity. In its report, Rx-360 noted that “globalization of all aspects of the pharmaceutical business has driven the need to address the threats of counterfeit or adulterated medication, devices and components, for which there have been several high-profile examples over the last few years.”</span>